ID   OVSAHO
AC   CVCL_3114
DR   BTO; BTO_0003502
DR   EFO; EFO_0006727
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-MTAB-2770
DR   BioSample; SAMN03472860
DR   BioSample; SAMN10988236
DR   cancercelllines; CVCL_3114
DR   Cell_Model_Passport; SIDM01377
DR   CGH-DB; 334-2
DR   DepMap; ACH-000409
DR   EGA; EGAS00001000610
DR   GEO; GSM459648
DR   GEO; GSM659398
DR   GEO; GSM887489
DR   GEO; GSM888571
DR   IARC_TP53; 28252
DR   JCRB; JCRB1046
DR   JCRB; NIHS0299
DR   JCRB; NIHS0341
DR   LiGeA; CCLE_754
DR   Millipore; SCC294
DR   PharmacoDB; OVSAHO_1227_2019
DR   PRIDE; PXD003105
DR   PRIDE; PXD003668
DR   Progenetix; CVCL_3114
DR   Wikidata; Q54937035
RX   PubMed=9328139;
RX   PubMed=11121861;
RX   PubMed=15677628;
RX   PubMed=17671176;
RX   PubMed=22460905;
RX   PubMed=23839242;
RX   PubMed=25485619;
RX   PubMed=25877200;
RX   PubMed=26589293;
RX   PubMed=26972028;
RX   PubMed=27141528;
RX   PubMed=27561551;
RX   PubMed=28196595;
RX   PubMed=30485824;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=31395879;
RX   PubMed=31978347;
RX   PubMed=32612269;
RX   PubMed=35918200;
WW   Info; MCLP; -; https://tcpaportal.org/mclp/
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: MD Anderson Cell Lines Project.
CC   Part of: TCGA-110-CL cell line panel.
CC   Population: Japanese.
CC   Doubling time: 56 hours (PubMed=9328139; PubMed=11121861); ~3 days (Note=Lot 09282010), ~43 hours (Note=Lots 04062015 and 12012017) (JCRB=JCRB1046).
CC   HLA typing: A*26:01,26:01; B*39:01,39:01; C*07:02,07:02; DQA1*01:02,01:02; DQB1*06:02,06:02; DRB1*03:02,15:01 (PubMed=26589293).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Arg342Ter (c.1024C>T); ClinVar=VCV000182970; Zygosity=Homozygous (DepMap=ACH-000409).
CC   Omics: Genomics; Whole exome sequencing.
CC   Omics: Genomics; Whole genome sequencing.
CC   Omics: Proteomics.
CC   Omics: Proteomics; Expression; Reverse-phase protein array.
CC   Omics: Proteomics; PTM; GPI-anchored proteins.
CC   Omics: Proteomics; Quantitative.
CC   Omics: Transcriptomics; Microarray.
CC   Omics: Transcriptomics; RNAseq.
CC   Omics: Variations; SNP array analysis.
CC   Genome ancestry: African=0%; Native American=0%; East Asian, North=83.52%; East Asian, South=14.27%; South Asian=0.06%; European, North=0%; European, South=2.15% (PubMed=30894373).
CC   Discontinued: JCRB; NIHS0299; true.
CC   Discontinued: JCRB; NIHS0341; true.
CC   Derived from site: Metastatic; Abdomen; UBERON=UBERON_0000916.
ST   Source(s): JCRB=JCRB1046; Millipore=SCC294; PubMed=25877200; PubMed=30485824
ST   Amelogenin: X
ST   CSF1PO: 10,12
ST   D13S317: 8
ST   D16S539: 9
ST   D18S51: 16,20
ST   D21S11: 31
ST   D3S1358: 15
ST   D5S818: 12,13
ST   D7S820: 8,10
ST   D8S1179: 11,14 (Millipore=SCC294)
ST   D8S1179: 14 (PubMed=25877200)
ST   FGA: 24
ST   Penta D: 9
ST   Penta E: 15
ST   TH01: 6
ST   TPOX: 8,11
ST   vWA: 14 (JCRB=JCRB1046; PubMed=25877200; PubMed=30485824)
ST   vWA: 14,16 (Millipore=SCC294)
DI   NCIt; C105555; High grade ovarian serous adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   56Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 10-04-25; Version: 35
//
RX   PubMed=9328139; DOI=10.1038/bjc.1997.471; PMCID=PMC2228076;
RA   Yanagibashi T., Gorai I., Nakazawa T., Miyagi E., Hirahara F.,
RA   Kitamura H., Minaguchi H.;
RT   "Complexity of expression of the intermediate filaments of six new
RT   human ovarian carcinoma cell lines: new expression of cytokeratin
RT   20.";
RL   Br. J. Cancer 76:829-835(1997).
//
RX   PubMed=11121861; DOI=10.1016/S0304-3835(00)00605-4;
RA   Ohta I., Gorai I., Miyamoto Y., Yang J., Zheng J.-H., Kawata N.,
RA   Hirahara F., Shirotake S.;
RT   "Cyclophosphamide and 5-fluorouracil act synergistically in ovarian
RT   clear cell adenocarcinoma cells.";
RL   Cancer Lett. 162:39-48(2001).
//
RX   PubMed=15677628; DOI=10.1093/carcin/bgi032;
RA   Gorringe K.L., Chin S.-F., Pharoah P.D.P., Staines J.M., Oliveira C.,
RA   Edwards P.A.W., Caldas C.;
RT   "Evidence that both genetic instability and selection contribute to
RT   the accumulation of chromosome alterations in cancer.";
RL   Carcinogenesis 26:923-930(2005).
//
RX   PubMed=17671176; DOI=10.1158/0008-5472.CAN-06-4567;
RA   Kikuchi R., Tsuda H., Kanai Y., Kasamatsu T., Sengoku K.,
RA   Hirohashi S., Inazawa J., Imoto I.;
RT   "Promoter hypermethylation contributes to frequent inactivation of a
RT   putative conditional tumor suppressor gene connective tissue growth
RT   factor in ovarian cancer.";
RL   Cancer Res. 67:7095-7105(2007).
//
RX   PubMed=22460905; DOI=10.1038/nature11003; PMCID=PMC3320027;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=23839242; DOI=10.1038/ncomms3126; PMCID=PMC3715866;
RA   Domcke S., Sinha R., Levine D.A., Sander C., Schultz N.;
RT   "Evaluating cell lines as tumour models by comparison of genomic
RT   profiles.";
RL   Nat. Commun. 4:2126.1-2126.10(2013).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5; PMCID=PMC4653878;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=26972028; DOI=10.1016/j.jprot.2016.03.008;
RA   Masuishi Y., Kimura Y., Arakawa N., Hirano H.;
RT   "Identification of glycosylphosphatidylinositol-anchored proteins and
RT   omega-sites using TiO2-based affinity purification followed by
RT   hydrogen fluoride treatment.";
RL   J. Proteomics 139:77-83(2016).
//
RX   PubMed=27141528; DOI=10.1016/j.dib.2016.04.001; PMCID=PMC4838930;
RA   Masuishi Y., Kimura Y., Arakawa N., Hirano H.;
RT   "Data for identification of GPI-anchored peptides and omega-sites in
RT   cancer cell lines.";
RL   Data Brief 7:1302-1305(2016).
//
RX   PubMed=27561551; DOI=10.1038/ncomms12645; PMCID=PMC5007461;
RA   Coscia F., Watters K.M., Curtis M., Eckert M.A., Chiang C.-Y.,
RA   Tyanova S., Montag A., Lastra R.R., Lengyel E., Mann M.;
RT   "Integrative proteomic profiling of ovarian cancer cell lines reveals
RT   precursor cell associated proteins and functional status.";
RL   Nat. Commun. 7:12645.1-12645.14(2016).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005; PMCID=PMC5501076;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//
RX   PubMed=30485824; DOI=10.1016/j.celrep.2018.10.096; PMCID=PMC6481945;
RA   Papp E., Hallberg D., Konecny G.E., Bruhm D.C., Adleff V., Noe M.,
RA   Kagiampakis I., Palsgrove D., Conklin D., Kinose Y., White J.R.,
RA   Press M.F., Drapkin R.I., Easwaran H., Baylin S.B., Slamon D.J.,
RA   Velculescu V.E., Scharpf R.B.;
RT   "Integrated genomic, epigenomic, and expression analyses of ovarian
RT   cancer cell lines.";
RL   Cell Rep. 25:2617-2633(2018).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747; PMCID=PMC6445675;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3; PMCID=PMC6697103;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. 3rd, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=31395879; DOI=10.1038/s41467-019-11415-2; PMCID=PMC6687785;
RA   Yu K., Chen B., Aran D., Charalel J., Yau C., Wolf D.M.,
RA   van 't Veer L.J., Butte A.J., Goldstein T., Sirota M.;
RT   "Comprehensive transcriptomic analysis of cell lines as models of
RT   primary tumors across 22 tumor types.";
RL   Nat. Commun. 10:3574.1-3574.11(2019).
//
RX   PubMed=31978347; DOI=10.1016/j.cell.2019.12.023; PMCID=PMC7339254;
RA   Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. 3rd,
RA   Kalocsay M., Jane-Valbuena J., Gelfand E.T., Schweppe D.K.,
RA   Jedrychowski M.P., Golji J., Porter D.A., Rejtar T., Wang Y.K.,
RA   Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A.,
RA   Sellers W.R., Gygi S.P.;
RT   "Quantitative proteomics of the Cancer Cell Line Encyclopedia.";
RL   Cell 180:387-402.e16(2020).
//
RX   PubMed=32612269; DOI=10.1038/s41598-020-67533-1; PMCID=PMC7329846;
RA   De Haven Brandon A.K., Box G., Hallsworth A., Court W., Matthews N.,
RA   Herodek B., Arteagabeitia A.B., Valenti M., Kirkin V.;
RT   "Identification of ovarian high-grade serous carcinoma cell lines that
RT   show estrogen-sensitive growth as xenografts in immunocompromised
RT   mice.";
RL   Sci. Rep. 10:10799.1-10799.13(2020).
//
RX   PubMed=35918200; DOI=10.1016/j.ygyno.2022.07.027;
RA   Hoare J.I., Hockings H., Saxena J., Silva V.L., Haughey M.J., Wood G.E.,
RA   Nicolini F., Mirza H., McNeish I.A., Huang W.-N., Maniati E.,
RA   Graham T.A., Lockley M.;
RT   "A novel cell line panel reveals non-genetic mediators of platinum
RT   resistance and phenotypic diversity in high grade serous ovarian
RT   cancer.";
RL   Gynecol. Oncol. 167:96-106(2022).
//